title: Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
abstract: OBJECTIVE
  To compare outcomes of nonnucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine or efavirenz versus abacavir-based regimens with a backbone of zidovudine and lamivudine as initial therapy of treatment-naive adults with HIV-1 infection in routine clinical care.
  
  
  METHODS
  All patients starting their first antiretroviral therapy with any of the studied regimens from January 1999 to December 2002 were included in the analysis. Rates of viral suppression (HIV-RNA below 50 copies/mL) and discontinuation of any component of the regimen were compared at 48 weeks.
  
  
  RESULTS
  Fifty-one patients started with one of the two NNRTI-based regimens and 49 started with the triple nucleoside regimen (3-NRTI). After 48 weeks, more patients in the NNRTI regimens (76.5%) than in the 3-NRTI (51.1%) regimen achieved a HIV-1 RNA level below the limit of detection (<1.7 log10 copies/mL; p = .008). Time to change the antiretroviral regimen was shorter with 3-NRTI (median [range]: 234 [139-329] days) than with NNRTI (346 [0-756] days) (p = .0901). More withdrawals related to drug toxicity or intolerance occurred with the 3-NRTI-based regimen.
  
  
  CONCLUSIONS
  In a routine clinical care setting, initial antiretroviral treatment with an NNRTI (nevirapine or efavirenz) plus zidovudine and lamivudine was virologically superior and safer than a 3-NRTI therapy (abacavir with the same NRTI backbone).
authors.affiliation: Department of Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain. mjperez@telefonica.net
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Dolores
authors.initials: D
authors.lastname: López
authors.forename: Antonio
authors.initials: A
authors.lastname: Antela
authors.forename: José Luis
authors.initials: JL
authors.lastname: Casado
authors.forename: Fernando
authors.initials: F
authors.lastname: Dronda
authors.forename: Carolina
authors.initials: C
authors.lastname: Gutiérrez
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Enrique
authors.initials: E
authors.lastname: Navas
authors.forename: Víctor
authors.initials: V
authors.lastname: Abraira
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Rodríguez
mesh_terms: D000328:Adult; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000254:growth & development*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D015999:Multivariate Analysis; D019829:Nevirapine / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D010349:Patient Compliance; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use; D000099227:Abacavir
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019259:Lamivudine; D019829:Nevirapine; D010078:Oxazines; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D000099227:Abacavir; C098320:efavirenz